Pacira BioSciences, Inc.
PCRX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $180 | $181 | $169 | $187 |
| % Growth | -0.9% | 7.2% | -9.8% | – |
| Cost of Goods Sold | $34 | $41 | $34 | $40 |
| Gross Profit | $145 | $140 | $135 | $147 |
| % Margin | 80.9% | 77.4% | 79.7% | 78.7% |
| R&D Expenses | $26 | $28 | $25 | $24 |
| G&A Expenses | $33 | $38 | $31 | $29 |
| SG&A Expenses | $92 | $89 | $87 | $80 |
| Sales & Mktg Exp. | $58 | $51 | $56 | $50 |
| Other Operating Expenses | $21 | $15 | $21 | $19 |
| Operating Expenses | $139 | $132 | $133 | $123 |
| Operating Income | $6 | $8 | $2 | $25 |
| % Margin | 3.5% | 4.7% | 1.2% | 13.2% |
| Other Income/Exp. Net | $3 | -$10 | $7 | $1 |
| Pre-Tax Income | $10 | -$2 | $9 | $26 |
| Tax Expense | $4 | $3 | $4 | $9 |
| Net Income | $5 | -$5 | $5 | $16 |
| % Margin | 3% | -2.7% | 2.8% | 8.6% |
| EPS | 0.12 | -0.11 | 0.1 | 0.35 |
| % Growth | 209.1% | -210% | -71.4% | – |
| EPS Diluted | 0.12 | -0.11 | 0.1 | 0.34 |
| Weighted Avg Shares Out | 44 | 45 | 46 | 46 |
| Weighted Avg Shares Out Dil | 44 | 45 | 47 | 49 |
| Supplemental Information | – | – | – | – |
| Interest Income | $9 | $5 | $7 | $6 |
| Interest Expense | $4 | $5 | $5 | $4 |
| Depreciation & Amortization | $21 | $27 | $21 | $21 |
| EBITDA | $34 | $29 | $34 | $51 |
| % Margin | 19.1% | 16.1% | 19.9% | 27% |